Pharma Industry News

FDA lifts clinical hold on Aptose blood cancer drug trial

Aptose Biosciences announced that the U.S. FDA has lifted the clinical hold on APTO-253, Aptose’s investigational drug for hematologic cancers.Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]